原发性醛固酮增多症严重程度分类与侧化及治疗结局的关联
本研究为回顾性多中心队列,纳入833例接受肾上腺静脉采血(AVS)的原发性醛固酮增多症(PA)患者,按PASC分为轻、中、重度。结果显示PASC严重程度与AVS定义的侧化呈阶梯式相关,且严重程度越高,手术或药物治疗的完全临床成功/缓解率越低,而生化结局无显著差异。
要点
- PASC严重程度与AVS侧化率呈阶梯式上升(19.2%、48.0%、76.1%)。
- 单侧PA手术后,重度患者完全临床成功率低于中度(31.3% vs 40.2%)。
- 双侧PA药物治疔,完全临床缓解率随严重程度增加而降低(36.8%、27.0%、8.8%)。
核心结论
- PASC定义的严重程度与AVS定义的侧化相关,且严重程度越高,完全临床成功或缓解率越低,但生化结局保持相似。
研究设计与样本
- 回顾性多中心队列研究,纳入8个三级中心共833例接受AVS的PA患者。
主要发现
- 833例中轻度52例(6.1%)、中度563例(67.6%)、重度218例(26.2%)。
- AVS定义侧化率随严重程度阶梯式增加:轻度19.2%、中度48.0%、重度76.1%(p < 0.001)。
- 单侧PA手术后,PASO临床结局因严重程度而异(p = 0.002),中度完全临床成功40.2%,重度31.3%,重度部分临床成功55.1%。
- 单侧PA手术后,PASO生化结局在各严重程度组间相似(p = 0.389)。
- 双侧PA药物治疗,PAMO临床结局因严重程度而异(p = 0.005),完全临床缓解率从轻度至重度递减:36.8%、27.0%、8.8%,生化结局可比(p = 0.993)。
临床怎么用
- PASC严重程度可辅助AVS决策,并提示术后或药物治疗的临床结局预期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The 2025 clinical guideline for primary aldosteronism (PA) recommends a diagnostic and therapeutic pathway stratified by lateralization risk. The PA severity classification (PASC) integrates biochemical and clinical features and is intended to inform graded recommendations for adrenal venous sampling (AVS). OBJECTIVE: We examined whether PASC is associated with AVS-defined lateralization and treatment outcomes. DESIGN: A retrospective multicenter cohort study. SETTING: Eight tertiary centers. PATIENTS: A total of 833 patients with PA who underwent AVS. PASC severity was classified as mild, moderate, or severe. MAIN OUTCOME MEASURES: We evaluated associations between severity, AVS-defined lateralization, and outcomes using the Primary Aldosteronism Surgical Outcome (PASO) and Primary Aldosteronism Medical Treatment Outcome (PAMO) criteria. RESULTS: Among 833 patients, 52 (6.1%), 563 (67.6%) and 218 (26.2%) had mild, moderate, and severe PA, respectively. Higher severity was associated with a stepwise increase in AVS-defined lateralizing PA (19.2%, 48.0%, and 76.1%, respectively; p < 0.001). In unilateral PA treated surgically, PASO clinical outcomes differed by severity (p = 0.002), with complete clinical success in 40.2% (moderate) and 31.3% (severe), and a marked increase in partial clinical success in severe disease (55.1%). PASO biochemical outcomes were similar across severity groups (p = 0.389). In bilateral PA treated medically, PAMO clinical outcomes varied by severity (p = 0.005), with complete clinical response decreasing from mild to severe disease (36.8%, 27.0%, and 8.8%), whereas biochemical outcomes were comparable (p = 0.993). CONCLUSIONS: PASC-defined severity correlated with AVS-defined lateralization. Greater severity was associated with lower rates of complete clinical success/response despite preserved biochemical outcomes, supporting a severity-informed framework to complement AVS in PA management.
引用
- Lee JH, Kim HY, Park MJ, et al. Association of the Primary Aldosteronism Severity Classification with Lateralization and Treatment Outcomes. J Clin Endocrinol Metab. 2026. PMID: 42375012. doi:10.1210/clinem/dgag259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。